LOC101060264 Silencing Suppresses Invasion and Metastasis of Human Colon Cancer.
CONCLUSIONS In summary, LOC101060264 silencing decreased LoVo cell invasiveness via suppressing ETM and attenuated tumor metastasis, which provides a novel therapeutic target for patients with colon cancer. PMID: 32077446 [PubMed - in process]
We report the genome-wide effects of KAP1 loss on the transcriptome, the chromatin state, and on recruitment of various components of the transcription machinery in the colon colorectal cancer cell line HCT116.
In this study, they compare two sequencing methods and design a bioinformatic analysis to establish the basis of a wide study in the research of early detection markers of colon cancer.
scu Berindan-Neagoe An increasing number of studies suggest the implication of microRNAs (miRNAs) in colorectal (CRC) carcinogenesis and disease progression. Nevertheless, the basic mechanism is not yet clear. We determined plasma miRNA expression levels using Agilent microarray technology followed by overlapping with The Cancer Genome Atlas (TCGA) tissue data and a qRT-PCR validation step and analysis of the altered miRNA signatures to emphasize new mechanistic insights. For TGCA dataset, we identified 156 altered miRNAs (79 downregulated and 77 upregulated) in colorectal tissue samples versus normal tissue. The mi...
British Journal of Cancer, Published online: 31 March 2020; doi:10.1038/s41416-020-0819-5Comment on: “Exploring the best treatment options for BRAF-mutant metastatic colon cancer”
Contributors : Dimitrios Iliopoulos ; Marina KoutsioumpaSeries Type : Non-coding RNA profiling by array ; Expression profiling by arrayOrganism : Homo sapiensTranscriptional lncRNAs expression comparing human colon cancer tissues to normal colon tissues using Agilent-062918 Human lncRNA array V4.0.
Journal of Natural ProductsDOI: 10.1021/acs.jnatprod.0c00003
CONCLUSIONS HtrA1 rs1049331 polymorphism, but not rs11200638 polymorphism, can influence individual sensitivity to 5-FU-based treatment in stage III colon cancer patients. PMID: 32218415 [PubMed - as supplied by publisher]
Colon cancer is one of the most common malignancies and the fourth leading cause of cancer-related mortality in the world. Colibactin, which is synthesized by the pks genomic island of E. coli interfere with the ...
Nanomedicine, Ahead of Print.
AbstractImmunoscore® is an in vitro diagnostic assay that is designed to predict the risk of relapse in patients with early-stage colon cancer, thus helping to guide treatment strategies. Immunoscore has CE-IVD status in the EU, is CLIA certified in the USA, and is commercially available in many other countries worldwide. It is designed to be used in conjunction with TNM staging. Immunoscore uses digital images of tumour samples and advanced software to quantify the densities of CD3+ and CD8+ lymphocytes in defined regions of the tumour (i.e. core tumour and the invasive margin). A risk score is calculated, with a lowe...